Solithromycin: A Novel Fluoroketolide for the Treatment of …
Solithromycin is a novel fluoroketolide developed in both oral and intravenous formulations to address increasing macrolide resistance in pathogens causing community-acquired bacterial pneumonia (CABP).
Solithromycin: Side Effects, Uses, Dosage, Interactions, Warnings - RxList
Solithromycin is an antibiotic currently undergoing clinical trials for the treatment of community-acquired bacterial pneumonia. Learn about uses, side effects, drug interactions, dosages, warnings, and more.
Efficacy and safety of oral solithromycin versus oral moxifloxacin …
2016年2月4日 · Solithromycin—a fourth-generation macrolide antibiotic with activity against macrolide-resistant CABP pathogens and potent immunomodulatory effects—was efficacious for treatment of CABP in a previous phase 2 trial and, in this global, phase 3, randomised controlled trial, was non-inferior to moxifloxacin for treatment of CABP.
Solithromycin: A novel ketolide antibiotic - Oxford Academic
2017年6月15日 · Solithromycin is a novel macrolide–ketolide with unique properties that confer activity against key CABP pathogens, including drug-resistant isolates. Concerns related to hepatotoxicity have put solithromycin’s ultimate approval and marketing in doubt.
FDA Accepts New Drug Application for Bacterial Pneumonia …
2016年7月6日 · The FDA recently accepted Cempra, Inc’s New Drug Application (NDA) for Solithera (solithromycin) for the treatment of community-acquired bacterial pneumonia (CABP). Solithromycin was found to be 8 to 16 times more potent …
Nature nurtures the design of new semi-synthetic macrolide antibiotics
2016年11月30日 · Solithromycin is poised to become a fourth-generation macrolide for use in community-acquired bacterial pneumonia, as it could be available in oral capsule and IV formulations.
Solithromycin (CEM-101): A New Fluoroketolide Antibiotic and Its …
2017年5月11日 · Solithromycin is a macrolide antibiotic that has undergone review for the treatment of community-acquired bacterial pneumonia. Solithromycin is also being investigated and has shown promise for the treatment of gonorrhea.
Solithromycin: A Novel Fluoroketolide for the Treatment of …
2016年12月1日 · Solithromycin, a novel fluoroketolide, covers the most common pathogens associated with CABP, including macrolide-resistant isolates. Similar to telithromycin, solithromycin inhibits protein synthesis as well as affecting ribosomal formation, and is thought to cause frame-shift mutations.
Metabolism, Excretion, and Mass Balance of Solithromycin in …
2018年4月26日 · Solithromycin, a novel macrolide and the first fluoroketolide, is being developed as a therapy for community-acquired bacterial pneumonia, with a distinct mechanism that provides activity against macrolide-resistant bacteria.
Solithromycin - an overview | ScienceDirect Topics
Solithromycin (Cempra Pharmaceuticals, Chapel Hill, NC) is a novel fluoroketolide, a fourth-generation macrolide agent demonstrating activity against pathogens resistant to earlier-generation macrolides, such as erythromycin and azithromycin.
- 某些结果已被删除